Bivigam
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Humoral Immune Response
Conditions
Humoral Immune Response
Trial Timeline
Dec 29, 2016 → Dec 31, 2022
NCT ID
NCT03164967About Bivigam
Bivigam is a approved stage product being developed by ADMA Biologics for Humoral Immune Response. The current trial status is completed. This product is registered under clinical trial identifier NCT03164967. Target conditions include Humoral Immune Response.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03164967 | Approved | Completed |
Competing Products
1 competing product in Humoral Immune Response
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MabThera + Physiological serum : sodium chloride, sodium citrate | Roche | Phase 3 | 77 |